Who Manufactures Salmeterol Xinafoate API?
The active pharmaceutical ingredient (API) salmeterol xinafoate is manufactured by several companies globally. These manufacturers supply the API to pharmaceutical companies that formulate it into finished drug products, such as inhalers for managing asthma and COPD [1].
What is Salmeterol Xinafoate Used For?
Salmeterol xinafoate is a long-acting beta-agonist (LABA) bronchodilator. It works by relaxing the muscles in the airways, which helps to open them up. This medication is used for the long-term management of bronchospasm in individuals with asthma or chronic obstructive pulmonary disease (COPD). It is typically prescribed in combination with an inhaled corticosteroid [2].
When Does Salmeterol Xinafoate's Patent Exclusivity End?
Information regarding patent exclusivity for salmeterol xinafoate can be found through resources like DrugPatentWatch.com, which tracks patent expirations and regulatory exclusivities for pharmaceutical products [3]. The exact expiry dates can vary based on specific patents, market exclusivities, and regulatory approvals in different regions.
Are There Generic Versions of Salmeterol Xinafoate Available?
Yes, generic versions of salmeterol xinafoate are available. Once patent protection and regulatory exclusivities expire, other pharmaceutical manufacturers can produce and market generic versions of the drug, often at a lower cost [4].
What are the Risks Associated with Salmeterol Xinafoate?
While effective, salmeterol xinafoate carries certain risks. A significant concern, particularly when used as monotherapy in asthma, is an increased risk of serious asthma-related events, including asthma-related death. For this reason, LABAs like salmeterol are generally recommended for use in asthma patients only in combination with an inhaled corticosteroid and not as a standalone treatment [2]. Other potential side effects can include throat irritation, hoarseness, headache, and tremor [5].
How Does Salmeterol Compare to Other Asthma Medications?
Salmeterol xinafoate belongs to the class of long-acting beta-agonists (LABAs). It is distinct from short-acting beta-agonists (SABAs), which provide quick relief from acute bronchospasm, and inhaled corticosteroids (ICS), which reduce airway inflammation. LABAs like salmeterol are designed for maintenance therapy to prevent symptoms, and their use in asthma typically involves co-administration with an ICS to mitigate risks and enhance bronchodilation [2].
What is the Mechanism of Action for Salmeterol Xinafoate?
Salmeterol xinafoate is a selective beta2-adrenergic agonist. It binds to beta2-adrenergic receptors on airway smooth muscle cells, stimulating adenyl cyclase. This leads to an increase in intracellular cyclic AMP (cAMP) levels, which ultimately causes relaxation of bronchial smooth muscle and bronchodilation [2].
Sources
1. Salmeterol Xinafoate API Manufacturers [1]
2. Salmeterol inhalation, oral [2]
3. DrugPatentWatch.com [3]
4. Generic drug information [4]
5. Salmeterol adverse effects [5]